QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.111146v1 320/1/22    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jiang, G.-L. Articles by Wheeler, L. Search for Related Content PubMed PubMed Citation Articles by Jiang, G.-L. Articles by Wheeler, L.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

The Prevention of Colitis by E Prostanoid Receptor 4 Agonist through Enhancement of Epithelium Survival and Regeneration

Departments of Biological Sciences (G.-L.J., A.N., W.B.I., L.W.) and Medical Chemistry (D.W.O., D.T.D.), Herbert Research Center, Allergan, Inc., Irvine, California

Inflammatory bowel disease (IBD) is often triggered and/or exacerbated by nonsteroidal anti-inflammatory drugs (NSAIDs). Among various prostanoids affected by NSAIDs, prostaglandin E₂ (PGE₂), in particular, seems to play critical roles in IBD via the EP4 receptor, one of the four PGE₂ receptor subtypes (EP1–4). An EP4 agonist, [[3-[[(1R,2S,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-butenyl]-5-oxocyclopentyl]thio]propyl]thio]-acetic acid, C₂₂H₃₀O₆S₂ (ONO-AE1–329), for example, when topically applied, has been reported to ameliorate typical colitis symptoms by suppressing the production of cytotoxic cytokines in the dextran sodium sulfate (DSS)-induced colitis model. EP4 agonists are also known, however, for their ability to protect epithelial cells from apoptosis in vitro, which may contribute to the protection of mucosal barrier functions. To investigate this potential application, we have tested another EP4-selective agonist in the DSS-indomethacin mouse colitis model. 7-[2-(3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-heptanoic acid methyl ester, C₂₃H₃₃NO₄ (AGN205203), an analog from the 8-azapiperidinone series of EP4 agonists, is metabolically and chemically more stable than the ONO agonist, because of its lack of oxidizable sulfur atoms in the -chain and of 11-OH group, a potential source of -elimination reaction. Treatment of mice subcutaneously with AGN205203 at 3 mg/kg/day minimized colitis symptoms, such as weight loss, diarrhea, and colonic bleeding. Further histological examination of colons revealed healthy surface columnar epithelial cells free of erosion and ulceration compared with those without the drug treatment. At cellular level, the drug treatment decreased colon epithelial apoptosis, prevented goblet cell depletion, and promoted epithelial regeneration. AGN205203 may be unique among known EP4 agonists for its metabolic and chemical stability, and it is amenable to systemic applications for the prevention and recovery of IBD.

Address correspondence to: Dr. Guang-Liang Jiang, Department of Biological Sciences, Herbert Research Center, Allergan, Inc., 2525 Dupont Dr., R&D3-2B, Irvine, CA 92612. E-mail: jiang_guang-liang{at}allergan.com

This article has been cited by other articles:

				A. F. Sheibanie, J.-H. Yen, T. Khayrullina, F. Emig, M. Zhang, R. Tuma, and D. Ganea The Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory Bowel Disease Is Mediated through the IL-23->IL-17 Axis J. Immunol., June 15, 2007; 178(12): 8138 - 8147. [Abstract] [Full Text] [PDF]